{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:12:47Z","timestamp":1774055567834,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejca.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T16:37:20Z","timestamp":1406997440000},"page":"2592-2601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"M.E.L.","family":"van der Burg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Onstenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Look","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"de Gooyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-8662","authenticated-orcid":false,"given":"L.G.M.","family":"Kerkhofs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.A.A.","family":"Valster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Ruit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.P.M.","family":"van Reisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.H.","family":"Goey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.E.","family":"van der Torren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-741X","authenticated-orcid":false,"given":"D.","family":"ten Bokkel Huinink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.C.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1062-4485","authenticated-orcid":false,"given":"H.C.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ejca.2014.07.015_b0005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2014.07.015_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2014.07.015_b0015","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2014.07.015_b0020","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2014.07.015_b0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1525-1438.2003.13357.x","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel\u2013cisplatin regimen over the cyclophosphamide\u2013cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2014.07.015_b0030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2014.07.015_b0035","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2014.07.015_b0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2014.07.015_b0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: phase III randomized study of sequential cisplatin\u2013topotecan and carboplatin\u2013paclitaxel vs carboplatin\u2013paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ejca.2014.07.015_b0050","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/annonc\/mds060","article-title":"First-line treatment of advanced ovarian cancer with paclitaxel\/carboplatin with or without epirubicin (TEC versus TC) \u2013 a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG","volume":"23","author":"Lindemann","year":"2012","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2014.07.015_b0055","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2014.07.015_b0060","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2014.07.015_b0065","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0959-8049(02)00242-3","article-title":"Dose-dense cisplatin\/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer","volume":"38","author":"de Jongh","year":"2002","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2014.07.015_b0070","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1054\/bjoc.2001.2014","article-title":"Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer","volume":"85","author":"Gelderblom","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2014.07.015_b0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6600002","article-title":"Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer","volume":"86","author":"van der Burg","year":"2002","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2014.07.015_b0080","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ejca.2012.11.027","article-title":"Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer","volume":"49","author":"van der Burg","year":"2013","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2014.07.015_b0085","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9698","key":"10.1016\/j.ejca.2014.07.015_b0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2014.07.015_b0095","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2014.07.015_b0100","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.07.015_b0105","unstructured":"NCI. Common Toxicity Criteria CTC version 2.0. Cancer Therapy Evaluation Program 1999:35."},{"issue":"8 Suppl. 1","key":"10.1016\/j.ejca.2014.07.015_b0110","first-page":"9","article-title":"Phase III trial of every-3-weeks paclitaxel vs dose dense weekly paclitaxel with carboplatin +\/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712)","volume":"23","author":"Chan","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2014.07.015_b0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/gyno.1993.1081","article-title":"A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish ovarian study group trial (DACOVA)","volume":"49","author":"Bertelsen","year":"1993","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.07.015_b0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-8258(92)90305-3","article-title":"Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma","volume":"45","author":"Hakes","year":"1992","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2014.07.015_b0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2014.07.015_b0130","first-page":"951","article-title":"A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer","volume":"10","author":"Takei","year":"2003","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejca.2014.07.015_b0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/pgs.11.140","article-title":"Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins","volume":"13","author":"Khrunin","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"24 Pt 1","key":"10.1016\/j.ejca.2014.07.015_b0140","first-page":"7067","article-title":"A Gompertzian model of human breast cancer growth","volume":"48","author":"Norton","year":"1988","journal-title":"Cancer Res"},{"issue":"5586","key":"10.1016\/j.ejca.2014.07.015_b0145","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/264542a0","article-title":"Predicting the course of gompertzian growth","volume":"264","author":"Norton","year":"1976","journal-title":"Nature"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2014.07.015_b0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/annonc\/4.suppl_4.S23","article-title":"Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery","volume":"4","author":"Levin","year":"1993","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2014.07.015_b0155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/00001813-200410000-00007","article-title":"Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?","volume":"15","author":"Lau","year":"2004","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2014.07.015_b0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2014.07.015_b0165","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J Clin Invest"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:07:24Z","timestamp":1565690844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914008156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0959804914008156"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}